PitchSend

Investor Presentaiton

R&D investor presentation Once-weekly insulin icodec displayed a similar safety profile to once-daily insulin glargine U100 in the phase 2 trial No statistically significant difference in the number of hypoglycaemic events between icodec and glargine U100 Severe or clinically significant hypoglycemia Events Rate Forest plot Icodec 38 52.6 Glargine U100 32 45.6 0.2 0.4 0.8 1.6 3.2 6.4 Favors Sema Favors Glargine U100 1 Estimated rate ratio with the 95% confidence interval 1.09 (0.45;2.65)1 12 222 Insulin icodec appeared to have a safe profile Rates of nocturnal events were low No cardiovascular events No new safety issues identified related to insulin icodec novo nordisk

View entire presentation